Disc Medicine financials
$65.87+1.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$236.0M | -$129.7M | -$91.1M | -$181.0K |
| Net income | -$212.2M | -$109.4M | -$76.4M | -$181.0K |
| Net margin | — | — | — | — |
| Diluted EPS | $-6.01 | $-3.96 | $-3.42 | $-0.11 |
| EBITDA | -$235.7M | -$129.6M | -$91.0M | -$181.0K |
| Operating cash flow | -$180.4M | -$93.9M | -$73.5M | — |
| Free cash flow | -$181.3M | -$94.4M | -$73.6M | — |
| Diluted shares | 35.3M | 27.6M | 22.3M | 1.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $91.1M | $192.4M | $360.4M | $0.00 |
| Short-term investments | $700.0M | $297.4M | $0.00 | $0.00 |
| Total debt | $29.2M | $28.3M | $0.00 | $0.00 |
| Total assets | $806.9M | $496.8M | $368.0M | $671.7K |
| Total liabilities | $67.1M | $53.2M | $22.9M | $847.0K |
| Shareholders' equity | $739.8M | $443.6M | $345.1M | -$175.4K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology